Second Plague Death Confirmed in Colorado
The Pueblo City-County Health Department has confirmed the death of an adult due to the plague.
Article Type: Listing
Xalkori Granted Breakthrough Therapy Designation By FDA
The Food and Drug Administration (FDA) granted Breakthrough Therapy designation to Xalkori (crizotinib; Pfizer) for the treatment of patients with ROS1-positive non-small cell lung cancer (NSCLC).
Sklice Lotion Now Available
Sanofi Pasteur announced that Sklice (ivermectin) Lotion, 0.5%, is now available for the treatment of head lice in patients 6 months of age and older.
FDA Approves Generic Gabapentin Oral Solution
Acella Pharmaceuticals announced that the FDA has approved Gabapentin oral solution 250mg/5mL, the generic equivalent of Pfizer’s Neurontin oral solution 250mg/5mL.
Phase 2b Study Update of Blisibimod for SLE
Anthera Pharmaceuticals announced the completion of dosing in its Phase 2b study of blisbimod for patients with systemic lupus erythematosus.
New warning and safety controls for long-acting beta agonists
The FDA announced that long-acting beta agonists (LABAs) should never be used alone in the treatment of asthma.
Phase 2 trial of plinabulin (NPI-2358) for the treatment of advanced non-small cell lung cancer (NSCLC)
Nereus Pharmaceuticals announced positive interim results from a randomized Phase 2 clinical trial evaluating the vascular disrupting agent (VDA) plinabulin (NPI-2358) in combination with standard chemotherapy (docetaxel) in patients with advanced non-small cell lung cancer (NSCLC).
Dextroamphetamine, amphetamine 20mg tablets recalled
Barr Laboratories has issued a voluntary recall of dextroamphetamine saccharate, amphetamine aspartate, dextroamphetamine sulfate and amphetamine sulfate (mixed salts of a single entity amphetamine product) 20mg tablets, 100 count bottles, Lot# 311756, distributed between June 11, 2009 and June 16, 2009.
Edluar approved for insomnia
The FDA has approved Orexo’s Edluar (zolpidem, [formerly known as Sublinox]), an imidazopyridine hypnotic, for the short-term treatment of insomnia characterized by difficulties with sleep initiation.
